A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...

Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Mylan, which has an established presence in the central nervous system therapy segment, is expected to leverage its network ...

HHS Secretary Robert F. Kennedy Jr. is preparing to remove committee members who advise the government on vaccine approvals ...

Pfizer has announced that it has entered into a marketing and supply agreement with Mylan Pharmaceuticals for the marketing and sale of two of its brands, Ativan and Pacitane.